E-cigarette use negatively affects lipids, myocardial blood flow
Click Here to Manage Email Alerts
PHILADELPHIA — Electronic cigarette use appears to have detrimental effects on lipid levels and myocardial blood flow compared with nonuse, according to two studies presented at the American Heart Association Scientific Sessions.
Lipid and glucose levels
Sana Majid, MD, postdoctoral fellow in vascular biology at Boston University School of Medicine, and colleagues conducted the CITU study to determine whether e-cigarette use affected lipid and glucose levels compared with no cigarette use.
“We know that traditional cigarette use tends to change glucose and cholesterol levels in an unfavorable direction, which may be a reason for the higher rates of heart disease in traditional cigarette smokers. We were interested in finding out whether electronic cigarettes are healthier for the heart or not,” Majid told Healio. “Measuring the association with glucose and lipid levels is one way to answer this question.”
The study included 94 nonsmokers, 45 e-cigarette smokers, 285 tobacco cigarette smokers and 52 dual cigarette users. All participants were aged 21 to 45 years, free from CVD and on no medications.
After adjustment for age, race and sex, sole e-cigarette use was associated with elevated total cholesterol and LDL compared with nonusers (P < .05 for all), and dual use was associated with lower HDL compared with nonusers (P < .05).
“Our findings suggest that even when people use e-cigarettes there may continue to be abnormal lipid levels. We need more studies to help us understand what happens over time when people switch from traditional cigarettes to e-cigarettes. Our study is part of a growing set of literature that suggests that e-cigarette use may not be heart healthy,” Majid said in an interview. “Many people, especially kids and teenagers, have the belief that e-cigarettes are harmless. We want everyone to know that there are many chemicals in e-cigarettes that may alter heart health. Our study is an early view suggesting that there may be a relation between e-cigarette use and an unhealthy cardiometabolic state.”
Myocardial blood flow
For the myocardial blood flow study, researchers analyzed 19 participants (mean age, 28 years) who were chronic users of e-cigarettes or tobacco cigarettes.
“We were highly motivated to do this research for two reasons,” Florian Rader, MD, medical director of the Human Physiology Laboratory and assistant director of the Non-Invasive Laboratory at the Smidt Heart Institute at Cedars-Sinai, told Healio. “First, we have always been interested in how smoking conventional tobacco cigarette changes the cardiovascular system and especially coronary microvascular physiology — which can be the earliest, even if hard to detect, sign of adverse effect. Second, having seen the incredibly fast uptake of e-cigarette use in our own local communities as well as across the country, we felt strongly compelled to find out how the effects of e-cigarettes compared to what we had seen for conventional cigarettes.”
After overnight abstinence, all participants underwent myocardial contrast echocardiography to measure the increase in myocardial blood flow after acute exposure to a tobacco cigarette or an e-cigarette. Participants were measured at rest and after performing a handgrip exercise to simulate physiological stress.
According to the researchers, in tobacco cigarette users, myocardial blood flow increased after smoke inhalation but sharply decreased with physiological stress, whereas in e-cigarette users, myocardial blood flow decreased at rest and with physiological stress.
“We believe the most important take-home message is that e-cigarettes are not completely safe,” Rader said in an interview. “They are certainly not safe for the lung, and our study results would suggest they are likely not safe for the heart.” – by Erik Swain
References:
Majid S, et al. Presentation Mo3196. Markers of Cardiovascular Health.
Rashid M, et al. Presentation Sa3199. Smoking, Alcohol Use and Other Behavioral Risk Factors for CVD. Both presented at: American Heart Association Scientific Sessions; Nov. 16-18, 2019; Philadelphia.
Disclosures: Majid reports no relevant financial disclosures. Rader reports he is a consultant for ReCor Medical.